The company said, “As previously disclosed, the Company is aware of a number of individual investigations by the Chinese authorities into current and former AstraZeneca (AZN) employees. To the best of the Company’s knowledge, the investigations include allegations of medical insurance fraud, illegal drug importation and personal information breaches. Recently Leon Wang, EVP International and AstraZeneca China President was detained. The Company has not received any notification that it is itself under investigation. If requested, AstraZeneca will fully cooperate with the Chinese authorities,”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca reports Q3 core EPS $2.08, consensus $1.03
- AstraZeneca now sees FY24 core EPS to increase by high teens percentage
- Tectonic Therapeutic price target raised to $69 from $49 at Leerink
- Options Volatility and Implied Earnings Moves This Week, November 11 – November 15, 2024
- QQQ ETF Update, 11/11/2024